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2-pore-domain potassium (K2P) channels 
modulate neuronal excitability throughout the 
entire CNS. The stretch-activated channel 
TREK1 (K2P2.1) is expressed widely in brain 
and has been linked to depression, 
neuroprotection, pain perception and epilepsy. 
Little, however, is known about the regulation 
of TREK1 expression on the transcriptional and 
translational level or about its trafficking to the 
plasma membrane. Here we have used PCR 
techniques to identify a splice variant of TREK1 
expressed in brain, which encodes a heavily 
truncated TREK1 protein retaining a single 
transmembrane domain. Functional expression 
of this splice variant TREK1Ex4 in tsA201 
cells in the presence or absence of wild type 
TREK1 revealed that TREK1Ex4 has no 
channel activity itself, but reduced TREK1 
whole-cell current amplitude. Confocal analysis 
of the expression of fluorescently-tagged 
TREK1 variants revealed that TREK1Ex4 is 
translated, but it is retained in the intracellular 
compartment. Additionally, TREK1Ex4 
reduced the level of TREK1 expression in the 
plasma membrane. Long and short forms of 
TREK1 derived from alternative translation 
initiation are differentially affected by 
TREK1Ex4, with the short form (lacking the 
first 41 amino acids at its N-terminus) 
unaffected. This differential regulatory role of 
TREK1Ex4 will alter the functional profile of 
TREK1 current in neurons where they are 
expressed. These results indicate that the N-
terminal domain and first transmembrane 
domain of TREK1 are likely to be important for 
channel dimerisation and trafficking to the 
plasma membrane.  
 
Modulation of the activity of 2-pore-domain 
potassium (K2P) channels is an important means of 
regulating neuronal excitability (1,2). The majority 
of the K2P channels (3), that are encoded by the 
KCNK genes have distinct expression patterns 
within the CNS (4-6) Activity of these ‘leak’ 
potassium channels is highly regulated by physical 
parameters such as heat, stretch or pH, as well as 
by lipids, G-protein-coupled receptors and 
anaesthetics (1,7-11). Particularly, members of the 
TASK and TREK channel subfamilies have been 
implicated in such diverse processes as, anaesthetic 
sensitivity, thermosensitivity, neuroprotection, pain 
perception and peripheral chemosensitivity (12-
19).  
 
K2P2.1, or TREK1, is widely expressed in brain (4-
6), and genetic ablation has revealed involvement 
of this channel in depression, neuroprotection, pain 
perception and ischemia-precipitated epilepsy 
(3,14,15,20-22). In rodents, TREK1 is prominently 
expressed not only in brain, but also in the lung, 
whereas expression levels in heart and kidney are 
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much lower (23). Functionally this channel is 
characterised by mechanosensitivity, heat 
sensitivity, G-protein regulation and activation by 
lipids, arachidonic acid and volatile anaesthetics 
(11,13,24,25).  
 
Whilst TREK1 is probably the most studied 2-
pore-domain potassium channel to date (21), there 
is still little known about the regulation of its 
functional expression both at a transcriptional, 
translational and post-translational level. A few 
recent studies have addressed its interaction with 
the A kinase anchoring protein 150 (AKAP150) or 
the microtubule-associated protein Mtap2 and the 
consequences for trafficking and targeting to 
specific regions of the cell membrane (26,27). 
Furthermore, both TREK1 and TREK2 have 
recently been shown to be the subject of alternative 
translation initiation (ATI) which produces 
channels differing in the length of their 
intracellular N-terminal domain and in their 
functional properties (28,29). These studies 
highlighted the importance of the N-terminal part 
of the channel for ion-selectivity and single 
channel conductance. In contrast, two TREK1 
splice variants of exon 1 isolated from rat cardiac 
muscle tissue, which differed by 15 amino acid 
residues in length of the N-terminus, showed 
identical biophysical properties (30). 
  
In the course of using PCR techniques to identify 
TREK-1 mRNA in specific brain regions, we 
detected a further splice variant within the first 
pore loop of TREK1, which leads to a predicted 
protein that is truncated before the second 
transmembrane domain. We demonstrate in tsA201 
cells that this mRNA is not degraded (31), but 
translated into a peptide that down-regulates 
functional expression of TREK1 channels. 
   
  
Experimental Procedures 
Molecular Biology- For mRNA isolation, adult 
male C57bl6 mice and 18-30 day-old Sprague-
Dawley rats of either sex were sacrificed in 
accordance with the Animals (Scientific 
Procedures) Act 1986. Briefly, animals were 
anaesthetised with halothane, decapitated, and the 
brain, lungs, heart, pancreas and liver rapidly 
removed and frozen on liquid nitrogen.  The frozen 
tissue was homogenized and mRNA isolated using 
a kit (Micro Fast Track, Qiagen). First strand 
cDNA was synthesized for 1 h at 37 C in reverse 
transcription buffer containing 5 µM random 
hexamer primers, 20 mM dithiothreitol, 0.5 mM 
(each) dNTPs, 20 U ribonuclease inhibitor 
(Promega) and 100 U Superscript II reverse 
transcriptase (Invitrogen). PCR amplification 
(Primers see Table 1) was carried out using a hot 
start protocol with Taq polymerase in a Perkin 
Elmer Thermal Cycler 9700 (30 cycles: 30 s at 94 
C, 1 min at 58 C, 2 min at 72 C). PCR samples 
were analysed by agarose gel electrophoresis and 
visualised using ethidium bromide. The PCR 
products were verified by direct sequencing 
(Eurofins MWG Operon, Ebersberg, Germany). 
Exons were numbered according to the reference 
sequences for mouse (NM_001159850.1) and 
human (NM_014217.3). This numbering includes 
an exon 1 before the start of the coding sequence. 
Previous studies (e.g. Li et al., 2006) had exon 1 as 
the exon that includes the start codon. 
Consequently, the splice variant TREK1Ex4 
described here, would have been named 
TREK1Ex3 under the alternative nomenclature. 
 
Mutagenesis- To generate a TREK1 cDNA lacking 
either exon 4 or its first 41 amino acids, a deletion 
mutagenesis strategy was utilised. A pair of 
complementary oligonucleotide primers, 30-40 bp 
long, composed of 15-20 bp of complementary 
sequence prior to the region being deleted and 15-
20 bp of complementary sequence, post the 
deletion region, were synthesised (Eurofins MWG 
Operon, Germany). PCR was then performed using 
a Quikchange site-directed mutagenesis kit and 
procedure (Stratagene, La Jolla, California). 
 
Wildtype TREK1 was cloned into the MCS site of 
pAcGFP1-N1 vector (clontech-Takara Bio Europe, 
France) to create a fusion construct with the N 
terminus of AcGFP1. The terminating stop codon 
of TREK1 was removed by site-directed 
mutagenesis and maintained in the same reading 
frame with the start codon of AcGFP1.  
 
TREK1Ex4 was cloned into the MCS of 
pDsRed2-N1 vector (clontech-Takara Bio Europe, 
France) to create a fusion construct with the N 
terminus of DsRed2. Site-directed mutagenesis was 
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used to delete all of the TREK1 sequence from and 
including the stop codon at positon 142, leaving 
105 AA of homologous TREK1 sequence and the 
37 AA frame-shifted tail in frame with the DsRed2 
protein. 
 
pDsRed-Monomer-Mem Vector  (clontech-Takara 
Bio Europe, France) encodes a fusion protein 
consisting of the DsRed-Monomer red fluorescent 
protein and the N terminal 20 amino acids of 
neuromodulin (or Gap 43). This fragment of 
neuromodulin contains a signal for post-
translational palmitoylation of cysteines 3 and 4, 
which targets DsRed Monomer to cellular 
membranes, and the plasma membrane in 
particular.  
 
Point mutations were produced using a site-
directed mutagenesis strategy (Stratagene, La Jolla, 
California).  
 
All constructs were fully sequenced (Eurofins 
MWG Operon) to ensure correct sequence 
incorporation, deletion and mutation. 
 
 Tissue culture- Modified HEK-293 cells (tsA201) 
were maintained in growth medium (Minimum 
Essential Medium enriched with 10ml per 500ml 
Penicillin–Streptomycin solution, 5ml per 500ml 
MEM Non Essential Amino Acids, 50ml per 500ml 
Foetal Bovine Serum and 2mM L-Glutamine) in 
5% CO2/95% O2 in a humidified incubator at 37C. 
When the cells were 80% confluent they were 
plated onto glass coverslips coated with poly-D-
lysine (1mg/ml). Transient transfection was carried 
out using the calcium phosphate method (32,33). In 
brief, 0.2-0.5 g cDNA encoding wildtype or 
mutant human TREK1 (Genbank AF171068; (34) 
This is isoform b, the shortest N-terminal human 
transcript, same start codon position as rodent) or 
TASK3 (Genbank Q9NPC2-1 (35)), or mouse 
Kir6.2 (Genbank D50581; (36,37)), and 0.2 g 
cDNA encoding for green fluorescent protein 
(GFP) were added to each 35 mm well. Cells were 
then incubated at 3% CO2/ 97% O2 for 12-18h. 
Subsequently, cells were washed twice with PBS 
and incubated in growth medium in 5% CO2/ 95% 
O2 in a humidified incubator at 37C for 24-96 h 
until use for electrophysiological recordings or 
confocal microscopy.  
Confocal microscopy- Cells were fixed with 4% 
PFA then washed with PBS before application of 
5µg/ml Hoechst 33258 nuclear dye (Invitrogen). 
Coverslips were rinsed with PBS and mounted onto 
slides using Mowiol mounting medium with 0.05% 
PPD. Images were taken with a Leica TCS SP2 
confocal microscope and processed using Image J 
software. Co-expression of transcripts was verified 
by randomly selecting >50 cells that expressed one 
transcript (e.g. GFP) and then evaluating what 
percentage of these expressed the other transcript 
(e.g. DsRed). This revealed co-expression in >95% 
of successfully transfected cells. Fluorescence 
intensity was read as an 8bit value (0 to 255) for 
each pixel as obtained from the camera. Membrane 
colocalisation was quantified via the Pearson’s 
correlation coefficient, determined using Image J 
WCIF software and the colocalisation plug-in 
[colocalisation test plug-in Tony Collins, Wayne 
Rasband]. The Pearson’s colocalisation coefficients 
were calculated for 5 membrane sections per cell 
and displayed as average of 5 cells +/- S.E.M.  
 
Electrophysiology- For electrophysiological 
recordings a coverslip with transfected tsA201 cells 
was transferred into a recording chamber mounted 
under an inverted microscope (Nikon Diaphot) 
with epifluorescence. During the course of the 
experiment cells were constantly superfused at 3-5 
ml/min with extracellular solution of the following 
composition (in mM): 145 NaCl, 2.5 KCl, 3 
MgCl2, 1 CaCl2, 10 HEPES (pH adjusted to 7.4 
with NaOH). Only cells that were successfully 
transfected with GFP as evident from green 
fluorescence (excitation: 395-440 nm, emission: 
470-600 nm) were selected for electrophysiological 
recordings.  
 
Patch pipettes were pulled from thin-walled 
borosilicate glass (GC150TF; Harvard Apparatus, 
Edenbridge, Kent, UK) and had resistances of 3-5 
M when filled with pipette solution. The pipette 
solution contained (in mM): 150 KCl, 3 MgCl2, 5 
EGTA, 10 HEPES (pH adjusted to 7.4 with KOH). 
Whole-cell currents were recorded at a holding 
potential of -60 mV at 20-24 C. Cells were 
hyperpolarised to -80 mV for 100 ms, then 
subjected to a step to -40 mV for 500 ms, followed 
by a step to -120 mV for 100 ms, followed by a 
500 ms voltage ramp to +20 mV, and a step back to 
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-80 mV for another 100 ms before being returned 
to the holding potential of -60 mV. This protocol 
was repeated every 5 s. Currents were recorded 
using an Axopatch 1D patch-clamp 
amplifier.(Molecular Devices, Sunnyvale, CA, 
USA), filtered at 0.3 kHz, digitised at 1 kHz and 
analysed using clampfit software (Molecular 
Devices) running on a personal computer. Whole-
cell capacitance was determined for every 
recording and current densities were calculated.  
 
Statistical analysis- Statistical analysis was 
performed using Origin7.5 (Origin Lab). All mean 
data is expressed as mean current density +/- 
S.E.M. To test for differences between groups two-
tailed unpaired t-test or one-way ANOVA followed 
by Bonferroni’s multiple comparison test were 
used as appropriate.  
 
RESULTS 
Identification of TREK1Ex4 splice variant by 
PCR. PCR analysis of TREK1 mRNA expression 
in rat and mouse using primers that anneal in exon 
3 and exon 5 revealed a prominent additional 
product of shorter length in brain tissue. Direct 
sequencing of both the long and short product 
revealed that the long product was the expected 
TREK1 PCR product, whereas the shorter product 
lacked exon 4 of TREK1. Interestingly, in other 
organs (heart, liver, kidney) the short product was 
either absent or produced at a much lower level. 
cDNA from pancreas was negative for TREK1 
(Fig. 1A). In mouse exon 4 of TREK1 encodes a 
portion of the extracellular/pore loop between 
transmembrane domains 1 and 2. It ends within the 
codon for the first ‘G’ of the ‘GFG’ signature 
sequence for 2-pore-domain potassium channels 
(Fig. 1B,C). Deletion of exon 4 (grey box) will not 
only destroy this signature sequence, but also cause 
a frame shift which generates a premature stop 
codon after 37 amino acid residues of exon 5 (Fig. 
2A). Consequently, translation of TREK1Ex4 
mRNA is expected to yield a protein with one 
transmembrane domain that is identical to the first 
104 amino acids of TREK1, followed by a tail of 
37 amino acids with a novel sequence due to the 
frameshift caused by deletion of exon 4. This 
protein is not expected to form functional channels, 
but the seemingly robust expression of 
TREK1Ex4 in rodent brain suggested to us that it 
might have some functional role. Consequently, 
this splice variant was mimicked by removing the 
sequence corresponding to exon 4 from the cDNA 
encoding human TREK1 and the mutant plasmid 
was transfected into tsA201 cells for 
electrophysiological analysis.  
 
Effects of TREK1Ex4 on TREK1 currents. Whole-
cell recordings from tsA201 cells transfected with 
wild type TREK1 cDNA under normal conditions 
gave current densities of 38 ± 2 pA/pF (n=76) 
(measured as the difference in holding current 
between that at -40 mV and that at -80 mV; Fig. 
2B,C).  Ramp changes in holding potential between 
-110 and -20 mV confirmed that the whole-cell 
current was outwardly rectifying and had a 
tendency to run down with time. This current had a 
reversal potential of -83+/-1 mV (n=70) close to 
the equilibrium potential for potassium ions under 
these recording conditions (Fig. 2D).  
 
In contrast, the TREK1 splice variant 
TREK1Ex4, with the whole of exon 4 missing, 
was found to be non-functional when expressed 
alone in tsA201 cells. The average current density 
amounted to 2 ± 1 pA/pF (n=14) and a reversal 
potential of -37 ± 3 mV in 2.5 mM potassium (Fig. 
2A-D). The current recorded from TREK1Ex4 
alone is undistinguishable from the current 
recorded from untransfected tsA201 cells (data not 
shown). 
 
Co-expression of wild type TREK1 and 
TREK1Ex4 somewhat surprisingly gave reduced 
(by 34%) whole-cell currents of 25 ± 2 pA/pF 
(n=17) when expressed in a 1:1 ratio. A further 
decrease (to 53% of wild type TREK1 expressed 
alone) in current (18 ± 3 pA/pF, n=23) was seen 
when wild type TREK1 and TREK1Ex4 were 
expressed in a 1:3 ratio (Fig. 2B,C). These results 
suggested that TREK1Ex4 might have some 
dominant-negative effect on TREK-1 expression.  
 
We also wanted to ensure that the dominant-
negative effect of TREK1Ex4 on TREK1 in 
tsA201 cells was not caused by the over-expression 
of a second non-functional potassium channel.  To 
do this we made use of the properties of the inward 
rectifier potassium channel Kir6.2. Like 
TREK1Ex4, Kir6.2 does not form functional 
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channels when expressed alone. The protein is 
made, but does not reach the plasma membrane in 
the absence of its regulatory subunit SUR1 (38). 
Here we demonstrate that, unlike TREK1Ex4, the 
presence of Kir6.2 does not affect the functional 
expression of TREK1 currents. TREK1 expressed 
on its own exhibited a current density of 35 ± 7 
pA/pF (n=12) and in the presence of Kir6.2 the 
current density for the outwardly-rectifying 
TREK1 current amounted to 41 ± 12 pA/pF (n=14; 
Fig. 2E). This difference was not significant and 
demonstrates that the expression of an unrelated 
protein that is unlikely to interact with TREK1 has 
no effect on the functional expression of TREK1. 
Secondly, to determine whether TREK1Ex4 
affected K2P channels from other subfamilies, we 
co-expressed it with wild type TASK3 channels. 
Measurement of current through TASK3 channels 
resulted in current densities of 104 ± 11 pA/pF 
(n=10) with a reversal potential of -89 ± 1 mV. 
Measurement of current from cells containing wild 
type TASK3 channels, co-expressed with 
TREK1Ex4 in a 1:1 ratio, resulted in current 
amplitudes of 89 ± 10 pA/pF (n=11) with a reversal 
potential of -83 ± 2 mV, demonstrating no 
significant change in current amplitude compared 
to wild type TASK3 channels alone (Fig. 2F). This 
agrees with previous data, that K2P channels from 
other subfamilies are unable to heterodimerise 
across subfamilies and consequently, we would 
postulate that TREK1Ex4 interacts specifically 
with TREK channels (39-43).  
 
Analysis of cellular localisation of TREK1 and 
TREK1Ex4. Next we explored further the nature 
of the dominant negative effect of TREK1Ex4 
upon TREK1. In order to determine whether 
TREK1Ex4 is translated and whether it is 
trafficked to the plasma membrane, GFP was fused 
to the C-terminus of TREK1. Similarly, DsRed2 
was fused to the C-terminus of TREK1Ex4. C-
terminal insertion of GFP did not interfere with 
TREK1 channel function. TREK1-GFP expressed 
large outwardly rectifying potassium currents (data 
not shown). 
 
Cellular localisation of TREK1-GFP and 
TREK1Ex4-DsRed2 was examined under a 
confocal microscope. GFP fluorescence was 
observed both at the surface membrane and 
internally in HEK293 cells transfected with 
TREK1-GFP (Fig 3Ai). First, mean whole cell 
fluorescence intensity from TREK1-GFP was 
determined for 14 cells without and 10 cells with 
co-expression of TREK1Ex4. The values of 92.29 
± 10.73 and 83.44 ± 7.97, respectively, were not 
statistically significantly different (p=0.545). These 
data suggested that the reduction in TREK1 whole 
cell current observed in the presence of 
TREK1Ex4 was not due to reduced translation of 
the protein. 
 
Expression in membrane was confirmed by 
coexpression with a fusion protein consisting of the 
DsRed red fluorescent protein monomer and the N-
terminal 20 amino acids of neuromodulin (DsRed-
Mem), which is specifically targeted to membranes 
(Fig 3Aii). Fig 3Aiii demonstrates visually the 
overlap in localisation between TREK1-GFP and 
DsRed-Mem. Similarly, Fig 3B shows that TREK1 
and TREK1Ex4 are highly co-localized when co-
expressed, but expression of TREK1 in the plasma 
membrane is greatly reduced. Co-localization was 
quantified using Pearson’s correlation (Fig 3Ci). 
The highest level of co-localization was found 
between TREK1 and TREK1Ex4, consistent with 
the idea that these two interact. A good correlation 
was detected between TREK1 and DsRed-Mem, 
indicating that TREK-1 is targeted to the plasma 
membrane. This correlation was significantly 
(p<0.05) reduced by co-expression with 
TREK1Ex4, consistent with the hypothesis that 
TREK1Ex4 subdues targeting of TREK1 to the 
plasma membrane. This is illustrated in Fig 3Cii, 
which shows reduced co-localisation of TREK1-
GFP and DsRed-Mem in the presence of unlabelled 
TREK1Ex4 (reduced levels of yellow at the 
plasma membrane). In contrast, when mean whole 
cell TREK1-GFP fluorescence was compared to 
mean whole cell DsRed-Mem fluorescence, the 
ratio was 1.00 ± 0.07 and 1.14 ± 0.09 in the 
absence and presence of TREK1Ex4, 
respectively, and thus remained unchanged 
(p=0.222). Again, this result indicated that 
TREK1Ex4 did not interfere with translation of 
TREK1. 
 
These experiments confirmed that the TREK1Ex4 
protein is made, but that its trafficking to the 
plasma membrane is impaired. TREK1 cannot act 
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as a chaperone, but the reduction in TREK1 whole 
cell currents suggests that TREK1 is likely to be 
retained in the intracellular compartment by 
interaction with TREK1Ex4.  
 
Truncated TREK1_Q105X mimicks TREK1Ex4. 
The TREK1Ex4 protein is identical to TREK1 up 
to residue Q104, which marks the end of exon 3. 
After this position TREK1Ex4 has a novel non-
homologous sequence of 37 residues. In order to 
determine whether this novel tail contributes to the 
properties of TREK1Ex4 a straight truncation was 
produced at the end of exon 3 (TREK1_Q105X; 
Fig 4A). This truncated protein was expressed in 
tsA201 cells either by itself, or in a threefold 
excess together with TREK1. Analysis of whole 
cell currents from these cells revealed that 
TREK1_Q105X expressed by itself is non-
functional (2 ± 1 pA/pF; reversal potential -37 ± 3 
mV; n=14) and that it is capable to significantly 
reduce TREK1 currents by 34% when co-expressed 
in a 3:1 ratio with TREK1 (Fig 4B,C). These 
results indicate that TREK1_Q105X interferes with 
TREK1 expression in a similar way to 
TREK1Ex4, and thus, that the novel tail of 
TREK1Ex4 plays only a minor role in its 
function.  
 
Effects of alternative translation initiation. TREK1 
channels are subject to alternative translation 
initiation (ATI). The human splice variant used in 
this study has an alternative translation initiation 
codon 42 amino acids upstream from the first 
methionine (Fig 5A). A study exploring the 
properties of such an N-terminal truncated TREK1 
variant found evidence for reduced potassium 
selectivity (28). We used this property to determine 
whether the N-terminal truncated ATI variant is 
made to a significant extent in our heterologous 
expression system.  
 
A point mutation was introduced into TREK1 that 
changed the ATI methionine into an isoleucine 
(TREK1_M42I), thus rendering the ATI non-
functional. When expressed in tsA-201 cells 
TREK_M42I produced whole cell current densities 
of 34 ± 2 pA/pF with a reversal potential of -84 ± 1 
mV (n=18), which is not significantly different 
from TREK1 (Fig. 5B,C). In contrast, the N-
terminal truncation TREK11-41 expressed alone 
showed a current density of 4 ± 1 pA/pF and a 
reversal potential of -70 ± 3 mV (n=18; Fig. 5D-F). 
This current density was too low to meaningfully 
test the effects of TREK1Ex4 on this mutant.  
 
In order to enhance these currents we made use of 
the histidine-modifying agent DEPC. DEPC has 
been shown to prevent inhibition of TREK1 by 
protons (44), thus leading to an increased current 
density at physiological pHe. The irreversible 
modification by DEPC followed a relatively slow 
time course that required application for several 
minutes for the maximal effect (see insert in Fig 
5F). The DEPC-enhanced current was outwardly-
rectifying, reversed at -100 ± 4 mV (n=4) and was 
not observed in untransfected tsA201 cells (n=5). 
Treatment with 0.1% DEPC led to a several-fold 
increase in current density for both TREK1_M42I 
and TREK11-41 (Fig. 5). In fact, after DEPC 
treatment TREK11-41 exhibited a mean current 
density of 50 ± 5 pA/pF and a reversal potential of 
-87 ± 2 mV (n=15), thus allowing analysis of the 
effects of TREK1Ex4 on TREK11-41 currents. 
 
Fig. 6A,B demonstrates that co-expression of 
TREK1Ex4 in a threefold excess failed to 
significantly reduce TREK11-41 currents both in 
the absence and presence of DEPC enhancement. 
In contrast, equivalent to TREK1, TREK1_M42I 
currents were significantly inhibited by co-
expression with TREK1Ex4 at a 1:3 ratio (Fig. 
6C,D). Current density under these conditions was 
32% smaller at 23 ± 3 pA/pF (n=13) with a reversal 
potential of -84 ± 2 mV. This effect persisted after 
DEPC enhancement (Fig. 6C,D). These results 
suggest that TREK1Ex4 fails to interact with 
TREK11-41 channels.  
 
DISCUSSION 
We have identified in rodent brain a splice variant 
of TREK1 that lacks exon 4. This splice variant 
removes part of the extracellular loop following 
TM1 and truncates the potassium channel signature 
sequence GFG of the first pore loop. It also causes 
a frameshift resulting in a premature stop codon 
after an additional 37 residues. The resulting 
truncated protein has only one TM. In accordance 
with this we observed no functional TREK-like 
currents when this splice variant was expressed in 
modified HEK cells. Surprisingly, however, co-
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expression of this splice variant with wild type 
TREK1 led to a reduction in TREK1 current 
density. This finding is indicative of a potential 
regulatory role of this splice variant upon stretch-




This splice variant has been isolated from human 
hippocampus cDNA before and has been posted in 
GenBank (AK123409) as ‘moderately similar to 
Homo sapiens TREK1 potassium channel 
(KCNK2) mRNA’. No functional analysis had 
been described. The fact that despite minor 
sequence differences this splice variant is 
consistently amplified from native brain tissue of 
different species (mouse, rat, human) strongly 
supports the view that this is indeed a splice variant 
rather than some sort of PCR artefact. Since both 
products will be amplified in one reaction sharing 
the same primers, it seems to be a valid assumption 
that the relative amount of PCR product obtained 
for the two cDNAs gives an indication of the 
relative abundance of the two mRNA species in the 
tissue they were isolated from. Based on this 
assumption it would appear that the splice variant 
constitutes a sizeable fraction of the TREK1 
mRNA in brain, but not in heart, liver, or kidney. 
However, since our study points at a direct 
interaction between the two splice variants of 
TREK1, accurate assessment of the potential 
impact of the splice variant in brain would require 
a quantitative comparison of TREK1 and 
TREK1Ex4 protein expression at the level of the 
individual neuron.  
 
To date one other report has described splice 
variants for TREK1: in heart two variants of exon 1 
are used, which leads to a differential proximal N-
terminus differing in length by 15 amino acid 
residues (30). However, there might well be more 
variation expected by analogy with TREK2 (45). 
 
Functional effects of the splice variant 
TREK1Ex4 on potassium currents 
TREK1Ex4 expression in tsA201 cells had a 
dominant-negative effect on TREK1, reducing 
whole-cell currents. Taken together with the lack of 
effect of Kir6.2 expression on TREK1 currents and 
the finding that TREK1Ex4 had no effect on 
TASK3 currents, this result suggests that this is not 
due to some unspecific effect on transcription or 
translation of TREK1. 
 
A similar observation has been made for TASK1 
channels. Hsu et al. (46) noticed a high sequence 
similarity between part of the HIV-1 accessory 
protein Vpu and the N-terminal portion of TASK1. 
They noticed that Vpu suppressed TASK1 currents 
and discovered that a truncated version of TASK1, 
consisting only of the N-terminus and the first TM, 
also strongly suppressed TASK1 currents 
heterologously expressed in HEK293 cells. Our 
discovery of the TREK1 splice variant suggests 
that this suppression of current by a truncated 
channel protein comprising only the first TM is 
indeed utilised by neurons in vivo to limit/regulate 
current density for 2PK channels.      
 
Given that TREK1Ex4 is not a functional 
potassium channel itself, it could feasibly reduce 
TREK1 currents either by reducing the number of 
TREK1 channels that reach the plasma membrane, 
i.e. interfere with trafficking, or it could bind to the 
functional TREK1 channel like a -subunit to alter 
its biophysical properties, e.g. reduce the open 
probability of the channel.  
 
From our confocal microscopy experiments with 
fluorescently-tagged TREK1 we know that 
TREK1Ex4 is translated, but that the protein is 
retained in internal membranes. We also know 
from these experiments that TREK1 cannot act as a 
chaperone to allow TREK1Ex4 to traffic to the 
plasma membrane. On the contrary, TREK1Ex4 
appears to retain TREK1 in internal membranes. 
Consequently, it appears most likely that 
TREK1Ex4 reduces surface expression of 
TREK1, rather than modulate its biophysical 
properties. At presence, our knowledge about 
transcriptional and translational regulation, as well 
as trafficking of 2-pore domain K
+
 channels is in its 
infancy (27,47-49) and we could only speculate 
whether unmasking of an ER retention signal 
would cause the reduced surface expression. A 
sequence of negative charges (EDE) in the 
proximal C-terminus has been identified as a 
positive signal crucial for TASK3 channel 
trafficking to the surface membrane in Xenopus 
oocytes (48). However, such a sequence is not 
present in the C-terminus of TREK1. In contrast, 
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the intracellular C-terminal sequence of TREK1 
contains several stretches of positive charges 
(RRR, KRK) which might act as ER retention 
signals (50). Alternatively, by analogy to what has 
been found for KATP channels, dimerisation might 
be required to mask this retention signal and allow 
trafficking to the plasma membrane (51). 
Alternatively, a different protein partner might bind 
to this part of TREK1 and thus mask the retention 
signal and allow trafficking to the plasma 
membrane. A recent study by Sandoz and 
colleagues (27) suggests that the microtubule-
associated protein Mtap2 does exactly this for 
TREK1 and TREK2, but not TRAAK channels.  
 
The coatamer protein complex 1 (COP1) has been 
suggested to promote the retention of TASK 
channels in the ER by binding to the N-terminus 
dibasic motif ((M)KR; (52,53); but see (54)), 
whilst the chaperone protein 14-3-3 binds to the 
extreme C-terminus of the channel causing COP1 
to dissociate from it (54,55).  Thus the presence of 
the N-terminus of TASK channels without the C-
terminus will promote retention in the ER. In 
contrast, the N-terminal intracellular sequence 
retained in TREK1Ex4 contains no such potential 
ER retention motif, nor does it contain the EDE 
trafficking signal. This suggests that a different 
mechanism retains this protein in internal 
membranes. It also seems unlikely that the frame-
shifted sequence after M1 of TREK1Ex4 is 
essential for the observed suppression of current, 
because expression of the simply truncated protein 
TREK1_Q105X had a similar inhibitory effect. 
However, TREK1_Q105X’s slightly reduced effect 
as compared to TREK1Ex4 suggests that a larger 
size construct might be more effective at inhibiting 
TREK1. We cannot tell whether TREK1Ex4 
interacts with a fully formed TREK1 dimer and 
prevents its surface expression, or whether 
TREK1Ex4 binds to individual TREK1 subunits 
which then fail to dimerise to fully functional 
channels. At present it is also impossible for us to 
tell which intracellular compartment TREK1 is 
trapped in by co-expression with TREK1Ex4. 
Further analysis of this splice variant might shed 
more light onto these issues. 
Significance for ATI 
Our results very clearly show that TREK1Ex4 has 
no effect on N-terminally truncated TREK 
channels derived from the alternative translation 
initiation described by Thomas et al (28). Thus in 
cells were both isoforms are present, TREK1Ex4 
would only downregulate the full length channel. 
Interestingly, Thomas et al (28) describe a reduced 
selectivity for potassium for the N-terminal 
truncated channel when expressed in Xenopus 
oocytes. In our hands, when expressed in tsA201 
cells, especially after enhancement with DEPC, no 
difference to the full length channels TREK1 and 
TREK1_M42I was seen when comparing reversal 
potentials at different external K
+
 concentrations 
(Supplementary Material). The more positive 
reversal potential observed in the absence of DEPC 
seems to reflect the larger contribution of the 
tsA201 cell intrinsic background conductance to 
the small TREK11-41 currents, rather than a 
reduced K
+
 selectivity of the channel itself. 
Whether the discrepancy with the study in xenopus 
oocytes (28) is due to expression of the channel in 
mammalian instead of amphibian cells in our 
experiments, remains to be determined. 
 
On a molecular level the only difference between 
the long and short forms of TREK1 derived from 
ATI is the lack of the first 41 amino acids at the N-
terminus of the short form. The large difference in 
current density between the two forms suggests 
that this region influences either the functional or 
trafficking properties of the channel (or both, see 
also (28,29)). The large increase in current density 
of the short form in the presence of DEPC does, 
however, suggest that a considerable number of 
channels are trafficked to the membrane. The lack 
of effect of TREK1Ex4 on the short form 
suggests that these first 41 amino acids are 
necessary for the interaction with TREK1Ex4, 
either because this region interacts directly with 
TREK1Ex4 or else because the presence of this 
region alters the conformation of the long form to 
allow interaction with TREK1Ex4. 
Conclusions 
The results presented here demonstrate that a 
heavily truncated potassium channel subunit that 
shows no ion conductance itself, can still be 
translated and have unexpected regulatory effects 
on related proteins. The differential regulatory role 
of TREK1Ex4 on the long and short form of 
TREK1 suggests that expression of this splice 
variant will alter the functional profile of TREK1 
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current in neurons where they are expressed, 
thereby regulating the functional properties and 
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Fig. 1. Expression pattern of TREK1Ex3. 
A. RT-PCR analysis of TREK1 (K2P2.1, KCNK2) expression in mouse and rat. In mouse a 383 bp band 
corresponds to TREK1 and a 265 bp band corresponds to TREK1Ex4(*). In rat a 574 bp band signifies 
TREK1 and a 456 bp band indicates TREK1Ex4(*). TREK1 was amplified from brain, heart, liver and 
kidney, but not from pancreas. TREK1Ex4 was more prominent in brain than in heart, liver and kidney, 
where it was seen only as a spurious product. B. Nucleotide and amino acid sequence of mouse TREK1 
(Genbank U73488) in the vicinity of exon 4. Nucleotides contributing to exon 4 are shown in a grey box. 
Note that exon 4 ends with the first nucleotide of the triplet encoding for the first glutamine of the ‘GFG’ 
K-channel signature sequence. Loss of exon 4 leads to a frameshift and a premature Stop codon (TAG) 
after a further 37 amino acids. This suggests that TREK1Ex4 encodes a heavily truncated protein 
consisting of only one TM and an extracellular tail. Amino acid residues that are different in the human 
sequence are indicated in bold. Numbering according to the human sequence is shown on the right 
(Genbank AF171068). C. Membrane topology of TREK1. The position of exon 4 between TM1 and the 
pore sequence GFG is indicated in black. 
 
Fig. 2. TREK1 Ex4 produces no functional current and reduces TREK1 currents. 
A. Topology of TREK1Ex4. This variant consists of an homologous N-terminus, TM1 and small part of 
the M1P1 loop up to the glutamine at position 105 (Q105), followed by 114 bp of frame shifted sequence, 
which encodes for 37 amino acid residues (see inset) and a stop codon. In total TREK1Ex4 is composed 
of 675 bp of coding sequence. B. Representative traces from TREK1- and TREK1Ex4-transfected 
tsA201 cells with the voltage protocol employed in this study. C. Mean current densities for TREK1, 
TREK1Ex4 and co-expression of TREK1 and TREK1Ex4 at the ratios indicated, calculated from the 
difference in holding current between -80 mV and -40 mV. TREK1 current density was significantly 
reduced in a concentration dependent manner, when co-expressed with TREK1Ex4. D. Current-voltage 
relationships for TREK1, TREK1 co-expressed (1:3 ratio) with TREK1Ex4 and TREK1Ex4 alone. E. 
Co-expression of the inward rectifier Kir6.2 with TREK1 does not reduce the TREK1 current density. 
Note that Kir6.2 does not form functional K
+
 channels in the absence of its -subunit SUR. F. Mean 
current density of TASK3 (K2P3.2, KCNK9) was not significantly affected by co-transfection with 
TREK1Ex4 at a 1:3 ratio. N-numbers are given above the bars. *: p<0.05; **: p<0.01. 
 
Fig. 3. Evaluation of cellular localisation of fluorescently labelled TREK1 variants. 
A. Photomicrographs showing cellular localisation of TREK1 tagged with GFP (TREK1-GFP; i) relative 
to the location of the membrane label DsRed-Mem (ii) determined by confocal microscopy. Nuclei were 
stained with the blue fluorescent dye Hoechst 33258. Overlay (iii) indicates strong co-localisation of 
TREK1-GFP and DsRed-Mem in yellow. B. Co-localisation of TREK1-GFP and TREK1Ex4 tagged 
with DsRed2 (TREK1Ex4-DsRed2) in individual tsA201 cell. Cells were transfected with both 
constructs in a 1:1 ratio. Note the strong co-localisation indicated by yellow fluorescence (iii). Ci. 
Quantification of the co-localisation observed in experiments as shown in A and B. A correlation 
coefficient of 1 indicates complete overlap of fluorescence, whereas a coefficient of -1 indicates no co-
localistion at all. Cii. Example of reduced co-localisation between TREK1-GFP and DsRed-Mem in the 
presence of unlabelled TREK1Ex4 (1:1 ratio with TREK1-GFP). White scale bar: 10 m. *: p<0.05 as 
compared to ‘TREK1-GFP+DsRed-Mem’.  
 
Fig. 4. Truncation of TREK1 at glutamine 105 replicates dominant negative effect of TREK1Ex4 on 
TREK1.  
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A. Topology of TREK1_Q105X, an N-terminal fragment of TREK1 with a stop codon inserted at 
glutamine 105 (Q105X). It differs in structure from TREK1Ex4 by lacking the additional 37 amino 
acids of frame shifted sequence following from the glutamine at position 104 (see also figure 2). B. 
Current density of TREK1, TREK1_Q105X and TREK1 co-expressed (1:3 ratio) with TREK1_Q105X. 
TREK1 whole cell current was significantly reduced, when co-expressed with TREK1_Q105X. C. 
Current-voltage relationships for TREK1 and TREK1 co-expressed with TREK1_Q105X. N-numbers are 
given above the bars. *: p<0.05; **: p<0.01. 
 
Fig 5. Effects of alternative translation initiation on TREK1 currents and their modification by DEPC.  
A. Topology of TREK1_M42I. This mutation removes the alternative start codon at position 41, ensuring 
only a complete full length channel is transcribed. B. Mean current densities of TREK1, TREK1_M42I 
and TREK1_M42I after exposure to 0.1% DEPC. C. Current-voltage relationships for TREK1_M42I 
before and after exposure to 0.1% DEPC. D. Topology of TREK11-41, where the first 41 amino acids 
have been deleted, resulting in an N-terminally truncated TREK1 channel, with M42 becoming the only 
translation start point of the channel. E. Current density of TREK1, TREK11-41 and TREK11-41 after 
DEPC modification. F. Current-voltage relationships for TREK1, TREK11-41 and TREK11-41 after 
DEPC exposure. Arrows indicate the shift in reversal potential observed for TREK11-41 currents after 
DEPC towards that observed for TREK1 currents. Insert shows the timecourse of DEPC-induced increase 
in TREK11-41 current. N-numbers are given above the bars. **: p<0.01 compared to TREK1; ##: 
p<0.01 compared to absence of DEPC. 
 
Fig. 6. TREK1Ex4 does not affect TREK11-41 currents. 
A. Current-voltage relationships for TREK11-41 alone and co-expressed with TREK1Ex4 following 
pre-incubation with 0.1%DEPC. B. Mean current density (pA/pF) for TREK11-41 was not significantly 
affected by co-expression with TREK1Ex4 at a 1:3 ratio with or without pre-incubation in DEPC. C. 
TREK1Ex4 significantly reduced TREK1_M42I currents after pre-incubation with 0.1%DEPC. D. 
Mean current density (pA/pF) for TREK1 alone and co-expressed with TREK1Ex4 at a 1:3 ratio 




Table 1. PCR primers used to amplify TREK1 fragments from rat and mouse cDNA. The forward primer 
was designed to bind within exon 2 and the reverse primer to bind in exon 4. 
 Forward primer Reverse primer Product size 
Mouse 
TREK1 
GTCCTCTACCTGATCATCGGAGC CCTAGCTGATCACCAACCCC   383 bp 
Rat TREK1 GTCCTCTACCTGATCATCGGAGC CCACAAAGTAGATGGCGTCCAGG 574 bp 
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